Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) have been assigned an average rating of “Moderate Buy” from the thirteen brokerages that are covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $55.5556.

TERN has been the subject of several recent analyst reports. Barclays upped their target price on Terns Pharmaceuticals from $36.00 to $56.00 and gave the company an “overweight” rating in a report on Tuesday, December 9th. Truist Financial boosted their price objective on Terns Pharmaceuticals from $35.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday, December 9th. BMO Capital Markets raised their target price on Terns Pharmaceuticals from $35.00 to $54.00 and gave the company an “outperform” rating in a research report on Tuesday, December 9th. UBS Group upgraded Terns Pharmaceuticals to a “strong-buy” rating in a research note on Thursday, December 4th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Terns Pharmaceuticals in a report on Monday.

Terns Pharmaceuticals Price Performance

TERN opened at $40.59 on Wednesday. Terns Pharmaceuticals has a fifty-two week low of $1.87 and a fifty-two week high of $48.26. The firm has a market capitalization of $3.66 billion, a P/E ratio of -39.41 and a beta of -0.24. The company’s 50-day moving average is $27.70 and its 200 day moving average is $13.89.

Terns Pharmaceuticals (NASDAQ:TERN) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.03. On average, equities research analysts expect that Terns Pharmaceuticals will post -1.19 earnings per share for the current year.

Insider Buying and Selling at Terns Pharmaceuticals

In other news, Director Jill M. Quigley sold 24,520 shares of the stock in a transaction that occurred on Tuesday, November 4th. The shares were sold at an average price of $18.00, for a total transaction of $441,360.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Terns Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of TERN. Engineers Gate Manager LP bought a new stake in shares of Terns Pharmaceuticals in the second quarter valued at $41,000. Canada Pension Plan Investment Board bought a new position in shares of Terns Pharmaceuticals during the 2nd quarter worth $46,000. LeConte Wealth Management LLC purchased a new stake in Terns Pharmaceuticals in the 2nd quarter worth about $47,000. Dynamic Technology Lab Private Ltd bought a new stake in Terns Pharmaceuticals in the 1st quarter valued at about $51,000. Finally, Velan Capital Investment Management LP raised its stake in Terns Pharmaceuticals by 17.6% in the 2nd quarter. Velan Capital Investment Management LP now owns 20,000 shares of the company’s stock valued at $75,000 after acquiring an additional 3,000 shares during the period. 98.26% of the stock is owned by institutional investors.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.